Allergan and Paratek Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) to review Seysara (sarecycline) for the treatment of moderate to severe acne vulgaris in patients 9 years of age and older. Seysara is a once-daily, oral, narrow spectrum tetracycline-derived antibiotic with anti-inflammatory properties for the potential treatment of moderate to severe acne in the community setting.   “The FDA’s NDA accepta...